Mouse Genome Informatics
cx1
    Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1tm2(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae

involves: 129S4/SvJae * C57BL/6
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
mortality/aging
• most mice die within 2 months following doxycycline treatment

hematopoietic system
• seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• seven weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• seven weeks after doxycycline treatment

growth/size
• following doxycycline treatment

immune system
• seven weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment

Mouse Models of Human Disease
OMIM IDRef(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085


Mouse Genome Informatics
cx2
    Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae

involves: 129S4/SvJae * C57BL/6
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
mortality/aging
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment (J:179085)

hematopoietic system
• seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• seven weeks after doxycycline treatment

growth/size
• following doxycycline treatment
• less pronounced than in homozygous mice

immune system
• two and seven weeks after doxycycline treatment

Mouse Models of Human Disease
OMIM IDRef(s)
Diamond-Blackfan Anemia 1; DBA1 105650 J:179085